Oxidatively modified low‐density lipoproteins are potential mediators of proteasome inhibitor resistance in multiple myeloma
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Cancer"
DOI: 10.1002/ijc.33497
Abstract: Proteasome inhibitor (PI) therapy has improved the survival of multiple myeloma (MM) patients. However, inevitably, primary or acquired resistance to PIs leads to disease progression; resistance mechanisms are unclear. Obesity is a risk factor for… read more here.
Keywords: multiple myeloma; proteasome inhibitor; resistance; oxldl ... See more keywords
An investigation of the mechanisms underlying the proteasome inhibitor bortezomib resistance in PC3 prostate cancer cell line
Sign Up to like & getrecommendations! Published in 2019 at "Cytotechnology"
DOI: 10.1007/s10616-019-00362-x
Abstract: The phenomenon of acquired resistance to chemotherapeutic agents is a long-standing conundrum in cancer treatment. To help delineate drug resistance mechanisms and pave the way for the development of novel strategies, we generated a PC3… read more here.
Keywords: proteasome inhibitor; pc3 prostate; bortezomib; resistance ... See more keywords
Proteasome Inhibitor-Related Cardiotoxicity: Mechanisms, Diagnosis, and Management
Sign Up to like & getrecommendations! Published in 2020 at "Current Oncology Reports"
DOI: 10.1007/s11912-020-00931-w
Abstract: Purpose of Review Multiple myeloma is the second most common hematologic malignancy in the USA, with over 32,000 new cases and nearly 13,000 deaths expected in 2019. The past few decades in myeloma research have… read more here.
Keywords: proteasome inhibitor; related cardiotoxicity; cardiotoxicity mechanisms; cardiotoxicity ... See more keywords
Proteasome Inhibitor PS-341 Effectively Blocks Infection by the Severe Fever with Thrombocytopenia Syndrome Virus
Sign Up to like & getrecommendations! Published in 2019 at "Virologica Sinica"
DOI: 10.1007/s12250-019-00162-9
Abstract: Severe fever with thrombocytopenia syndrome (SFTS) is an emerging hemorrhagic fever disease caused by SFTSV, a newly discovered phlebovirus that is named after the disease. Currently, no effective vaccines or drugs are available for use… read more here.
Keywords: proteasome inhibitor; severe fever; thrombocytopenia syndrome; infection ... See more keywords
Proteasome inhibitor b-AP15 induces enhanced proteotoxicity by inhibiting cytoprotective aggresome formation.
Sign Up to like & getrecommendations! Published in 2019 at "Cancer letters"
DOI: 10.1016/j.canlet.2019.02.003
Abstract: Proteasome inhibitors have been shown to induce cell death in cancer cells by triggering an acute proteotoxic stress response characterized by accumulation of poly-ubiquitinated proteins, ER stress and the production of reactive oxygen species. The… read more here.
Keywords: proteasome inhibitor; inhibitor; ap15; proteotoxicity ... See more keywords
Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Medicinal Chemistry"
DOI: 10.1021/acs.jmedchem.0c00499
Abstract: Visceral leishmaniasis is responsible for up to 30,000 deaths every year. Current treatments have shortcomings that include toxicity and variable efficacy across endemic regions. Previously, we reported the discovery of GNF6702, a selective inhibitor of… read more here.
Keywords: proteasome inhibitor; inhibitor; proteasome; kinetoplastid selective ... See more keywords
Discovery of a Novel Oral Proteasome Inhibitor to Block NLRP3 Inflammasome Activation with Anti-inflammation Activity.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.2c00523
Abstract: NLRP3 inflammasome activation plays a critical role in inflammation-related disorders. More small-molecule entities are needed to study the mechanism of NLRP3 inflammasome activation and to validate the efficacy and safety of the NLRP3 pathway. Herein,… read more here.
Keywords: inflammation; proteasome inhibitor; inflammasome activation; nlrp3 inflammasome ... See more keywords
Inhibition of NGLY1 Inactivates the Transcription Factor Nrf1 and Potentiates Proteasome Inhibitor Cytotoxicity
Sign Up to like & getrecommendations! Published in 2017 at "ACS Central Science"
DOI: 10.1021/acscentsci.7b00224
Abstract: Proteasome inhibitors are used to treat blood cancers such as multiple myeloma (MM) and mantle cell lymphoma. The efficacy of these drugs is frequently undermined by acquired resistance. One mechanism of proteasome inhibitor resistance may… read more here.
Keywords: proteasome inhibitor; inhibitor; inhibition; transcription factor ... See more keywords
Mitochondrial metabolism promotes adaptation to proteotoxic stress
Sign Up to like & getrecommendations! Published in 2019 at "Nature chemical biology"
DOI: 10.1038/s41589-019-0291-9
Abstract: The mechanisms by which cells adapt to proteotoxic stress are largely unknown, but are key to understanding how tumor cells, particularly in vivo, are largely resistant to proteasome inhibitors. Analysis of cancer cell lines, mouse… read more here.
Keywords: proteasome inhibitor; stress; proteotoxic stress; mitochondrial metabolism ... See more keywords
H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth
Sign Up to like & getrecommendations! Published in 2019 at "Scientific Reports"
DOI: 10.1038/s41598-019-40635-1
Abstract: The second-in-class proteasome inhibitor (PI) carfilzomib (Kyprolis, Cfz) has contributed to a substantial advancement in multiple myeloma treatment by improving patient survival and quality of life. A considerable portion of patients however display intrinsic resistance… read more here.
Keywords: cfz; h727 cells; proteasome inhibitor; inhibitor carfilzomib ... See more keywords
Exosomes mediate intercellular transfer of non–autonomous tolerance to proteasome inhibitors in mixed‐lineage leukemia
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Science"
DOI: 10.1111/cas.14351
Abstract: Proteasome inhibitors significantly improve cancer outcomes, but their use is eventually followed by proteasome inhibitor resistance and relapse. Current understanding of proteasome inhibitor resistance is limited to cell‐autonomous mechanisms; whether non–autonomous mechanisms can be implicated… read more here.
Keywords: proteasome inhibitor; inhibitor resistance; inhibitor; mixed lineage ... See more keywords